-
Maintain Zubsolv® revenues.
-
Approval and launch of OX124.
-
Milestone payments and royalties from current and future partnered products.
Strategy for growth
Every day, we strive to build a broader and stronger Orexo. By doing so, we can improve many more lives, foster a more dynamic work environment, and generate value for our shareholders. Our efforts to strengthen and expand Orexo are built on three pillars and are driven by our ambition to contribute to a more sustainable world for all.
1. Growing revenues and profit contributions
2. Improving access to treatment
- Expand reimbursement of Zubsolv in the public segment and maintain access in the commercial segment.
- Secure reimbursement for OX124 at launch.
- Establish collaborations under MATCore to provide innovative solutions that improve access to OUD treatment.
3. Capitalize on the AmorphOX drug delivery technology
- Partnering with other pharmaceutical companies to co-develop new products based on AmorphOX®.
- Out-license the AmorphOX technology.
- Develop new products for Orexo to commercialize primarily within OUD and adjacent diseases/conditions.
Sustainability strategy
Orexo’s business strategy and its day-to-day operationalization are shaped by the company’s Ethical Code. The strategy supports Agenda 2030 and the Sustainable Development Goals (SDGs). It is also aligned with global standards and initiatives, including the International Labor Organization Conventions, and the UN Guiding Principles on Business and Human Rights. The sustainability strategy consists of four focus areas: